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Background: Mesenchymal stromal cells (MSCs) are attractive for cell-based therapies ranging from regenerative
medicine and tissue engineering to immunomodulation. However, clinical efficacy is variable and it is unclear how
the phenotypes defining bone marrow (BM)-derived MSCs as well as donor characteristics affect their functional
properties.
Methods: BM-MSCs were isolated from 53 (25 female, 28 male; age: 13 to 80 years) donors and analyzed by:
(1) phenotype using flow cytometry and cell size measurement; (2) in vitro growth kinetics using population
doubling time; (3) colony formation capacity and telomerase activity; and (4) function by in vitro differentiation
capacity, suppression of T cell proliferation, cytokines and trophic factors secretion, and hormone and growth factor
receptor expression. Additionally, expression of Oct4, Nanog, Prdm14 and SOX2 mRNA was compared to pluripotent
stem cells.
Results: BM-MSCs from younger donors showed increased expression of MCAM, VCAM-1, ALCAM, PDGFRβ, PDL-1,
Thy1 and CD71, and led to lower IL-6 production when co-cultured with activated T cells. Female BM-MSCs showed
increased expression of IFN-γR1 and IL-6β, and were more potent in T cell proliferation suppression. High-
clonogenic BM-MSCs were smaller, divided more rapidly and were more frequent in BM-MSC preparations from
younger female donors. CD10, β1integrin, HCAM, CD71, VCAM-1, IFN-γR1, MCAM, ALCAM, LNGFR and HLA ABC
were correlated to BM-MSC preparations with high clonogenic potential and expression of IFN-γR1, MCAM and HLA
ABC was associated with rapid growth of BM-MSCs. The mesodermal differentiation capacity of BM-MSCs was
unaffected by donor age or gender but was affected by phenotype (CD10, IFN-γR1, GD2). BM-MSCs from female
and male donors expressed androgen receptor and FGFR3, and secreted VEGF-A, HGF, LIF, Angiopoietin-1, basic
fibroblast growth factor (bFGF) and NGFB. HGF secretion correlated negatively to the expression of CD71, CD140b
and Galectin 1. The expression of Oct4, Nanog and Prdm14 mRNA in BM-MSCs was much lower compared to
pluripotent stem cells and was not related to donor age or gender. Prdm14 mRNA expression correlated positively
to the clonogenic potential of BM-MSCs.
Conclusions: By identifying donor-related effects and assigning phenotypes of BM-MSC preparations to functional
properties, we provide useful tools for assay development and production for clinical applications of BM-MSC
preparations.
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More than 40 years ago Alexander Friedenstein de-
scribed cells that could be isolated from the bone mar-
row (BM) and cultured as fibroblastoid colony forming
cells ex vivo [1,2]. Depicted as mesenchymal stromal
cells (MSCs), these cells were shown to support
hematopoiesis [3] and osteogenesis [4]. Since then, it has
become clear that BM-MSCs offer promising therapeutic
potential in regenerative medicine and immunotherapy
[5-7]. The most commonly applied technology in re-
search and clinic to isolate and culture BM-MSCs from
fresh BM is the removal of non-adherent BM cells and
subsequent expansion of the adherent BM-MSCs (BM-
MSC preparations) [6,8-10]. Studies reporting on varia-
tions in the growth kinetics and gene expression of BM-
MSC preparations obtained from different donors [11],
variable properties of BM-MSC clones [12], and surface
markers identifying BM-MSC subpopulations, such as
CD173, CD271, GD2, stage-specific embryonic antigen
(SSEA)-4, or mesenchymal stem cell antigen (MSCA)-1
[13-15], highlighted the heterogeneity of MSC prepara-
tions. Moreover, their mechanisms of action are still not
fully elucidated. Recently, MSC therapies have come
under criticism [16] as, despite decades of research, rele-
vant translational questions of MSC biology and func-
tion remain unanswered. Many studies reported on the
osteogenic, adipogenic and chondrogenic differentiation
potential and the immunomodulatory properties of BM-
MSCs [15,17,18]; however, controversies prevail about
their myogenic or even non-mesodermal differentiation
capacity [10,19,20]. In vivo efficacy paired with poor sur-
vival and homing rate to the damaged tissue points to-
ward mechanisms that most presumably are mediated
by factors secreted by BM-MSCs [21,22]. Recently, more
straightforward studies reported on gene expression pro-
filing and phenotype of freshly sorted CD271+ cells from
the BM, and some transcripts appeared to be related to
the donor age [23,24]. However, the presence or absence
of one single marker as like as CD271 does not suffi-
ciently define all BM-MSC subpopulations within hu-
man BM-MSC preparations. Therefore, clarification of
how the phenotypes defining BM-MSC subpopulations,
as well as age and gender of donors, might affect func-
tional properties of BM-MSCs would mark a significant
step forward in our understanding of BM-MSC biology.
However, different isolation/expansion technologies/re-
agents [15] and donor-to-donor variations [11] result in
variable fractions of MSC subpopulations per donor/
preparation and hamper reliable statistical analyses.
Therefore, we obtained BM-MSC preparations from 53
donors of both genders. These multiple BM-MSC prepa-
rations were isolated using the most commonly applied
technology in research and the clinic [6,8-10], that is, re-
moval of non-adherent BM cells and expansion of theadherent mononuclear BM cells. The BM-MSCs were
cultured under identical conditions and analyzed at early
passage for phenotype, proliferation capacity, cell size,
clonogenic potential, differentiation potential, immuno-
modulatory potential, secretion of trophic factors, gene
expression profile and telomerase activity. Hereby,
donor-to-donor variations and variations within the BM-
MSC preparations could be identified; however, the great
number of BM-MSC preparations allowed statistically
robust correlation analyses of phenotype, donor gender
and age to functional properties of BM-MSCs.
Methods
Isolation and culture of human BM-MSCs
Human BM-MSCs were isolated and cultured as de-
scribed previously [14]. After written informed consent
and approval of the ethical committee of the University
Hospital Tübingen, Germany, BM from patients without
metabolic or neoplastic diseases was obtained during
orthopedic operations. BM mononuclear cells were iso-
lated by density gradient centrifugation on Lymphoflot
(Biotest, Dreieich, Germany), washed twice with PBS
(Lonza, Walkersville, MD, USA), counted and seeded at
a density of 1 × 105 cells per cm2 in standard culture
medium (SCM), composed of α-MEM (Lonza), 1%
penicillin-streptomycin (Lonza) and 10% pooled human
blood group AB serum (PHS) (ZKT Tübingen,
Germany), to tissue culture flasks (Nunc, Roskilde,
Denmark). The average concentrations of sex hormones
in the PHS (obtained only from male donors) were in
the normal ranges for male individuals above 15 years
(testosterone: 16.18 nmol/l; estradiol (eE2): 106.8 pmol/l;
estrone (E1): 169.4 pmol/l) and the average bFGF con-
centration was 75.12 pg/ml. The resulting passage (P)0
cultures were kept under standard culture conditions at
37°C in humidified atmosphere with 5% CO2. Non-
adherent cells were removed after 24 hours and the ad-
herent cells were cultured in SCM. SCM was changed
twice a week until cells reached subconfluency, defined
as 90% surface coverage by cells corresponding to
15,000 to 20,000 cells per cm2. At this point, the BM-
MSCs were detached using Trypsin-EDTA (Lonza),
counted using a CASY® cell counter (Roche, Basel,
Switzerland) and plated to fresh tissue culture flasks for
the next passage (P1) at a density of 1,000 cells per cm2.
Flow cytometry
Flow cytometry analysis of all BM-MSC preparations
was performed at the end (subconfluency) of P1 with
a FACScan instrument (BD Biosciences, Franklin
Lakes, NJ, USA) using BD CellQuest Pro software
and the following (secondary) PE-labeled antibodies:
anti-CD10, -CD14, -CD19, -CD29, -CD31, -CD34,
-CD43, -CD44, -CD45, -CD56, -CD59, -CD71, -CD73,
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-CD119, -CD130, -CD140a, -CD140b, -CD146, -CD166,
-CD273, -CD274, -GD2, SSEA-1, -SSEA-4 and -HLA class
I (BD Biosciences); -CD93, -Galectin 1 (R&D Systems,
Minneapolis, MN, USA); -CD133 and -CD271 (Miltenyi
Biotec, Bergisch Gladbach, Germany); -CD243 (Chemicon
(Millipore Corporation), Billerica, MA, USA); -CD173
(AbD Serotec, Puchheim, Germany) and –MSCA-1
(BioLegend, San Diego, CA, USA). PE-conjugated or non-
labeled IgG1, -IgG2a, IgG3 and -IgM antibodies (BD Bio-
science) were used as isotype matched controls. Secondary
antibody was a polyclonal PE-conjugated goat anti-mouse
Ig (BD Bioscience). Dead cells were excluded by uptake of
7-Aminoactinomycin D (for gating strategy see Additional
file 1: Figure S4, for density plots see Additional file 2:
Figure S5). Analysis of percentage of antigen positive
cells and fluorescence intensity was performed using
FlowJo-7.2.5 software (Tree Star, Ashland, OR, USA).
For compensation of unspecific antibody binding, the
positivity of the respective matched isotype control was
subtracted from all samples.
Analysis of cell size and PDT
Cell count and analysis of cell size was performed at the
end of each passage using a CASY cell counter (Roche).
Population doubling time (PDT) during P1 was calcu-
lated by the equation PDT = (culture time*ln2)/ln(cell
numberharvested/cell numberseeded). Seeding density was
kept constant at 1,000 cells per cm2.
Colony forming assays
For assessment of colony formation capacity, subconfluent
primary BM-MSCs (P0) were trypsinized, counted and
seeded at a density of 100, 200 and 500 cells per well (for
two MSC populations additional data points with 1,000
cells per well were acquired) in six-well plates at P1
(Nunc, Wiesbaden, Germany). To address possible effects
of seeding density on colony formation each MSC prepar-
ation was seeded at the aforementioned densities. Cells
were cultured during 10 days in MesenCult™ Proliferation
Kit (human) medium (Stem Cell Technologies, Vancouver,
BC, Canada), then fixed and stained with crystal violet
containing 4% formalin. Colonies containing >50 cells
were counted microscopically. The number of colonies
per 100 seeded cells (percentage colony formation) was
calculated for each seeding density for each MSC prepar-
ation. These percentages were averaged for each MSC
preparation (two experiments for each BM-MSC prepar-
ation) and used as one CFU-F data point for the respective
MSC preparation for statistical analysis.
In vitro differentiation assays
Functional characterization of BM-MSCs included in-
duction of adipogenic, osteogenic and chondrogenicdifferentiation in vitro as described previously [14].
Briefly, for adipogenic and osteogenic differentiation,
BM-MSCs were seeded at a density of 1,000 cells per
cm2 at P1 and kept under standard culture conditions
until reaching subconfluency. Subsequently, either
adipogenic differentiation was induced using the hMSC
Adipogenic BulletKit (PT-3004, Lonza), or osteogenic
differentiation was induced using “osteogenic medium”
composed of SCM with 10-8 M dexamethasone, 0.2 mM
ascorbic acid and 10 mM β-glycerolphosphate (Sigma).
After three weeks under differentiation conditions cells
were processed for RNA isolation or for lineage specific
staining: lipid vacuoles in adipogenic cultures were
stained with Oil Red O and calcium deposits of osteo-
genic cultures with Alizarin Red S, respectively.
For chondrogenic differentiation, 2.5 × 105 BM-MSCs
at P1 were kept in micromass pellet cultures for subse-
quent staining or in monolayer cultures for RNA isola-
tion respectively. Differentiation was induced using the
hMSC Chondrogenic Differentiation BulletKit (PT-3003,
Lonza), supplemented with TGF-β 3 (PT-4124, Lonza)
as a growth factor. After four weeks of differentiation,
cells were processed for RNA isolation or frozen sections
of fixed pellets were stained with Safranin O.
Quantitative RT-PCR
For quantitative analysis of lineage specific mRNA indi-
cative for adipogenic, osteogenic and chondrogenic dif-
ferentiation potential, as well as for expression analysis
of octamer-binding transcription factor (Oct4), Nanog,
PR domain containing (Prdm)14, sex determining region
Y-box (SOX)2, indoleamine 2,3-dioxygenase (IDO)1 and
IDO2 mRNA from differentiated and undifferentiated
BM-MSCs was isolated and reversely transcribed to
cDNA. To compare Oct4, Nanog, Prdm14 and SOX2
mRNA expression in BM-MSCs to pluripotent stem
cells, mRNA was isolated from the human pluripotent
teratocarcinoma cell line NCCIT (ATCC-CRL-2073, Ch#
5097030, ATCC, Manassas, VA, USA), and from the hu-
man pluripotent embryonic stem cell (hESC) line
HUES9 (generously provided by the Harvard Stem Cell
Institute, Cambridge, MA, USA). Quantitative PCR was
performed on resulting cDNA and gene expression was
normalized to the expression of the housekeeping gene
GAPDH for each sample. Gene induction for differenti-
ation markers was calculated by normalization of the
gene expression of differentiated cultures to undifferenti-
ated controls.
RNA isolation
RNA from adipogenic, osteogenic and chondrogenic dif-
ferentiated MSCs, as well as from undifferentiated BM-
MSCs (controls) at P1 was isolated using peqGOLD
TriFast according to the manufacturer’s instructions.
Siegel et al. BMC Medicine 2013, 11:146 Page 4 of 20
http://www.biomedcentral.com/1741-7015/11/146RNA for analysis of Oct4, Nanog, Prdm14, SOX2, IDO1
and IDO2 expression was extracted using the RNeasy
Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Remaining genomic DNA
was digested using the RNase-Free DNase Set (Qiagen).
RNA concentration was assessed using a NanoDrop
photometer (Thermo Scientific, Wilmington, DE, USA.
RNA was stored at −80°C for up to three months.
Reverse transcription
For analysis by quantitative PCR, 250 μg RNA from each
sample was reversely transcribed using the Transcriptor
First Strand cDNA Synthesis Kit (Roche) according to
the manufacturer’s instructions. Resulting cDNA was
stored at −20°C for up to six months.
Quantitative PCR
For the adipogenic differentiation markers LPL and
PPAR-γ, the osteogenic markers AP and OPN, and the
chondrogenic markers SOX9 and COLL2 as well as for
GAPDH as housekeeping gene, PCR analysis of cDNA
obtained from differentiated and undifferentiated BM-
MSC cultures was performed using ready-to-use amplifi-
cation primer mixes for RT-PCR (search-LC, Heidelberg,
Germany) in combination with LightCycler FastStart
DNA Master SYBR Green I (Roche) and the LightCycler
Instrument (Roche), according to the manufacturer’s in-
structions. Quantitative PCR assays for Oct4, Nanog,
Prdm14 and SOX2 expression of undifferentiated BM-
MSCs were performed in the same way.
For the PCR targets IDO1 and IDO2, primers were or-
dered from Sigma Aldrich (St. Louis, MO, USA) and used
in combination with the QuantiTect SYBR Green PCR Kit
(Qiagen). Primer sequences were CGGGACACTTTGCT
AAAGGCGCT and GGGGGTTGCCTTTCCAGCCAG
for IDO1 and CCTGCAGAGGTCCTGCCAAGGAA and
ATGCAGGCTCTCTCCCCCAGG for IDO2 cDNA. The
primer annealing step was performed at 60°C. PCR speci-
ficity for IDO1 and IDO2 was confirmed by product
sequencing (4base lab, Reutlingen, Germany).
PCR results were analyzed by normalizing the expres-
sion of each target gene to the expression of the house-
keeping gene GAPDH in each sample. Gene induction for
differentiation markers was calculated by normalization of
the gene expression of differentiated cultures to undiffer-
entiated controls.
T cell proliferation assays
The immunosuppressive properties of BM-MSCs were
analyzed in co-culture assays with activated allogeneic T
cells. BM-MSCs at P2 were mitotically inactivated by
treatment with 40 μg/ml mitomycin C for 30 minutes at
37°C in serum free medium. Thereafter, BM-MSCs were
washed three times in SCM and seeded into 96-wellplates (Nunc, Roskilde, Denmark) in triplicates at a
density of 2 × 104 cells per well. After 24 hours, 1 × 105
PBMNCs, freshly isolated by density-gradient centrifuga-
tion from heparinized blood of healthy donors and nor-
malized to the lymphocyte number, were added to the
appropriate wells of BM-MSC cultures. T cells were stim-
ulated by addition of 10 μg/ml Phytohaemagglutinin-L
(Sigma) and cultured for 72 hours under standard cul-
ture conditions. During the last six hours, 100 μM
Bromodeoxyuridine (BrdU) labeling solution from the
Cell Proliferation ELISA, BrdU (colorimetric) Kit
(Roche) was added to the (co-) cultures and cell prolif-
eration was assessed by the subsequent ELISA, using
the anti-BrdU antibody provided in the kit according to
the manufacturer’s instructions. Photometric light ab-
sorption was measured in a plate reader and absorb-
ance values were averaged and normalized to the
PBMNC only control of the respective blood donor. Su-
pernatants of T cell proliferation assays were collected
and stored at −80°C for subsequent analysis of cytokine
production.
Multiplex analysis of cytokine production
Cytokine production of BM-MSCs alone and of BM-
MSC-PBMNC co-cultures was analyzed in supernatants
of T cell proliferation assays. Samples of 25 μl cell cul-
ture supernatant were analyzed in triplicates using hu-
man cytokine/chemokine multiplex kits (Millipore)
according to the manufacturer’s instructions. The Kits
were composed of beads for detection of IL-2, IL-4, IL-6,
IL-8, IL-10, IFN-γ and TNF-α. Analysis was performed
using a Luminex® 200 instrument (Luminex Corporation,
Austin, TX, USA).
Analysis of trophic factor secretion
For evaluation of trophic factor secretion, BM-MSCs
MSCs from 11 unrelated donors (5 female, 6 male; age:
50.9 y ± 13.3 y) (P2) were seeded to six-well plates at a
subconfluent density of 20,000/cm2. The cells were kept
under standard culture conditions and the medium was
renewed after 24 hours to a precise volume of 3.0 ml per
well. After 72 additional hours, culture supernatants
were transferred to Eppendorf cups and frozen at −80°C
for subsequent cytokine analysis.
Samples were sent to Multimetrix (Heidelberg,
Germany) for multiplex analysis of HGF, LIF, VEGF-A,
bFGF and NGFB expression in a commercial Luminex®
system. Expression of BMP4 and Angiopoietin-1 was an-
alyzed with Quantikine™ ELISA systems (R&D Systems)
per the manufacturer’s instructions. ELISA standard
curves were aligned using a five-parameter logistic re-
gression model for sample quantification. Background
concentration of all factors was measured in complete
culture medium and subtracted from the detected
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both Luminex® analysis and ELISAs. All samples were
analyzed in technical duplicates.
Analysis of hormone and growth factor receptor
expression
For analysis of androgen receptor and FGFR3 expres-
sion, BM-MSCs from 14 unrelated donors (7 female, 7
male; age: 53.7 y ± 13.8 y) (P2) were seeded into 12-well
plates in a density of 20,000 cells/cm2 and kept under
standard culture conditions for 24 hours. Thereafter, the
cell monolayers were washed with ice cold PBS, lysed in
300 μl Procarta™ lysis buffer (Affymetrix, Santa Clara,
CA, USA) and frozen at −80°C.
Samples were analyzed for FGFR3 and androgen re-
ceptor content with ELISA systems (USCN Life Science,
Wuhan, China) per the manufacturer’s instructions.
ELISA standard curves were aligned using a five-
parameter logistic regression model for sample quantifi-
cation. Background concentration was measured in pure
lysis buffer and subtracted from the detected concentra-
tions of the respective cell lysates. All samples were ana-
lyzed in technical duplicates.
Telomerase activity assay
To quantify telomerase activity, the Telo TAGGG
Telomerase PCR ELISA kit (Roche Applied Science,
Mannheim, Germany), based on the Telomeric Repeat
Amplification Protocol (TRAP), was used on 2 × 105 BM-
MSCs at P1 according to the manufacturer’s instructions.
Samples were classified as telomerase negative when the
extinction value was <0.2 after subtracting the negative
control.
Statistical analysis
The statistical analyses were performed using ANOVA
analysis of variance, the Spearman two-tailed correlation
test, or the two-tailed Student’s t-test. Differences were
considered significant when P <0.05.
Results
BM-MSC preparations are composed of BM-MSC
subpopulations with a heterogenic phenotype
Flow cytometric analysis was performed with 38 BM-
MSC preparations (even distribution of gender and age
(20 male, age: 54.4 y ± 11.3 y SD; 18 female, age 50.3 y ±
16.9 y SD)) revealing three different patterns of surface
markers on the cells that composed the BM-MSC prepa-
rations in vitro: First, CD29, CD44, CD59, CD73, CD90,
CD105, CD140b, CD166 and HLA ABC were expressed
on the majority of cells within the MSC preparations
(>96%) (n = 33). Second, no or very few (≤0.5%) cells ex-
pressing CD14, CD19, CD34, CD43, CD45, CD86,
CD93, CD133, CD243 and SSEA-1 could be detectedin the BM-MSC preparations (n = 33 except for CD86
(n = 30)) (Figure 1A). In contrast to these two marker
groups, a third marker group showed a great hetero-
geneity of BM-MSC subpopulations expressing these
antigens (2.6% to 84.2%) within the respective BM-
MSC preparations with great standard variations be-
tween the BM-MSC preparations: CD10 (84.2% ±
11.7% SD), CD31 (6.2% ± 5.7% SD), CD56 (9.4%±7.0%SD),
CD71 (71.0% ± 14.4% SD), CD80 (5.5% ± 3.8% SD),
CD106 (76.4% ± 14.8% SD), CD119 (80.3% ± 10.9% SD),
CD130 (63.6% ± 13.3% SD), CD140a (31.5% ± 26.5% SD),
CD146 (77.7% ± 13.3% SD), CD173 (2.6% ± 3.3% SD),
CD271 (13.0% ± 9.8% SD), CD273 (56.9% ± 22.8% SD),
CD274 (37.8% ± 22.9% SD), Galectin 1 (60.8% ± 31.2%
SD), GD2 (35.3% ± 15.1% SD), MSCA-1 (80.0% ± 14.1%
SD), and SSEA-4 (6.8% ± 7.8% SD) (n = 33 except for
CD80 (n = 30), CD119 (n = 27), CD130 (n = 34), CD273
(n = 30), CD274 (n = 30), Galectin 1 (n = 24), and SSEA-4
(n = 36)) (Figure 1B).
Analyses of specific antibody mediated mean fluores-
cence intensity (MFI) per cell (ΔGeo Mean) showed that
the markers that were expressed on most of the cells
(Figure 1A) were also expressed at high density per cell
(Figure 1C). Here, CD90 could be identified as the
marker that was expressed at highest density per cell
(476.8 MFI ±212 SD). In the group of markers that showed
a heterogenic expression profile MSCA-1 was expressed at
highest density per cell (46.7 MFI ±38.8 SD) (n = 36 except
for CD80 (n = 32), CD86 (n = 32), CD119 (n = 29),
CD130 (n = 37), CD273 (n = 32), CD274 (n = 32),
Galectin 1 (n = 26), and SSEA-4 (n = 39)) (Figure 1D).
The phenotype of BM-MSCs from younger donors is
different compared to older donors
The percentage of CD71+, CD146+, and CD274+ cells
correlated negatively with the donor age indicating that
BM-MSC preparations from younger donors contained
more CD71+, CD146+, and CD274+ MSC subpopula-
tions compared to BM-MSC preparations from older do-
nors (n = 34 except for CD274 (n = 31)) (Figure 2A-C).
Similarly, the specific antibody mediated fluorescence
per cell (ΔGeo Mean) of CD71, CD90, CD106, CD140b,
CD146, CD166 and CD274 correlated negatively with
the donor age indicating that the expression of CD71,
CD90, CD106, CD140b, CD146, CD166 and CD274 per
cell was higher in BM-MSC preparations from younger
donors compared to MSC preparations from older do-
nors (n = 34 except for CD274 (n = 31)) (Figure 2D-J).
BM-MSC preparations from female donors contain more
CD119+ and CD130+ cells and smaller cells that divide
more rapidly
BM-MSC preparations from female donors harbored sig-
nificantly more CD119+ cells (86.8% ± 7.3% SD) (n = 11)
Figure 1 Flow cytometric analyses. The expression of CD10, CD14, CD19, CD29, CD31, CD34, CD43, CD44, CD45, CD56, CD59, CD71, CD73,
CD80, CD86, CD90, CD93, CD105, CD106, CD119, CD130, CD133, CD140a, CD140b, CD146, CD173, CD166, CD243, CD271, CD273, CD274, Galectin 1,
GD2, MSCA-1, SSEA-1, SSEA-4 and HLA class I was analyzed by flow cytometry in MSC preparations from multiple donors identifying three groups of
marker expression. Markers that were expressed on all/most of the cells or on none/very few of the cells within the respective MSC preparation
(A) and markers that identified MSC subpopulations by presence or absence of the respective marker (B) (n = 33 except for CD80 (n = 30), CD86
(n = 30), CD119 (n = 27), CD130 (n = 34), CD273 (n = 30), CD274 (n = 30), Galectin 1 (n = 24), and SSEA-4 (n = 36)). Analyses of specific antibody
mediated fluorescence per cell (ΔGeo Mean) identified markers that were expressed at high and low density per cell (C, D) (n = 36 except for CD80
(n = 32), CD86 (n = 32), CD119 (n = 29), CD130 (n = 37), CD273 (n = 32), CD274 (n = 32), Galectin 1 (n = 26), and SSEA-4 (n = 39)). ANOVA analysis of
variance followed by Tukey’s Multiple Comparison Test (***P <0.001). Error bars: SD.
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to BM-MSC preparations from male donors (CD119+
cells: 73.9% ± 13.1% SD (n = 17); CD130+ cells: 58.7% ±
13.2% SD (n = 19)) (Figure 2K,L). The diameter of
BM-MSCs from female donors (20.9 μm ± 0.8 μm SD)
(n = 14) was slightly but significantly smaller compared to
male donors (22.0 μm ± 1.1 μm SD) (n = 11) (Figure 3A).
The population doubling time (PDT) of BM-MSCs fromfemale donors (3.3 d ± 1.9 d SD) (n = 25) was significantly
reduced compared to BM-MSCs from male donors (5.0
d ± 3.7 d SD) (n = 27) (Figure 3B) indicating the pres-
ence of smaller, more rapidly dividing cells in BM-MSC
preparations from female donors compared to male do-
nors. This finding was confirmed by the positive correl-
ation of the cell size to the PDT (n = 25) (Figure 3C). No
correlation was found between the donor age and the
Figure 2 (See legend on next page.)
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Figure 2 Correlation analyses of marker expression to donor age and gender distribution. The percentage of CD71+, CD146+, and CD274+
cells and the specific antibody mediated fluorescence per cell (ΔGeo Mean) of CD71, CD90, CD106, CD140b, CD146, CD166 and CD274 correlated
negatively with the donor age (n = 34 except for CD274 (n = 31)) (A-J). Spearman two-tailed correlation test (*P <0.05; **P <0.01). MSC
preparations from female donors harbored significantly more CD119+ cells (n = 11) and CD130+ cells (n = 16) compared to MSC preparations
from male donors (CD119+ cells: n = 17; CD130+ cells: n = 19) (K, L). Two-tailed Student’s t-test (*P <0.05; **P <0.01). Error bars: SD.
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and between the donor age to the cell size (n = 25)
(Figure 3E).
BM-MSC preparations containing smaller cells are
composed of subpopulations that express surface
markers at a higher density
The specific antibody mediated fluorescence per cell
(ΔGeo Mean) of CD105, CD119, CD140a, CD166 and
HLA ABC correlated negatively with the cell sizeFigure 3 Analyses of cell size and growth kinetics. The diameter of MS
compared to male donors (n = 11) (A). The PDT of MSCs from female don
donors (n = 27) (B). Two-tailed Student’s t-test (*P <0.05). Error bars: SD. Th
correlation was found between the donor age and the proliferation capaci
(n = 25) (E). The specific antibody mediated fluorescence per cell (ΔGeo M
negatively with the cell size (n = 22 except for CD119 (n = 17)) (F-J). The s
CD105, CD119, and HLA ABC correlated negatively with the PDT (n = 27 ex
the percentage of CD146+ cells within the MSC preparations (n = 27) (N). S
****P <0.0001).indicating that the expression of these antigens was
higher on cells within BM-MSC preparations that con-
tain more small cells (n = 22 except for CD119 (n = 17))
(Figure 3F-J).
BM-MSC preparations containing more rapidly dividing
cells are composed of subpopulations that express
surface markers at a higher density
The specific antibody mediated fluorescence per cell
(ΔGeo Mean) of CD105, CD119 and HLA ABCCs from female donors (n = 14) was slightly but significantly smaller
ors (n = 25) was significantly reduced compared to MSCs from male
e cell diameter correlated positively to the PDT (n = 25) (C). No
ty of the MSCs (n = 52) (D) and between the donor age to the cell size
ean) of CD105, CD119, CD140a, CD166 and HLA ABC correlated
pecific antibody mediated fluorescence per cell (ΔGeo Mean) of
cept for CD119 (n = 21)) (K-M). The PDT correlated negatively with
pearman two-tailed correlation test (*P <0.05; **P <0.01; ***P <0.001;
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expression of these antigens was higher on cells within
BM-MSC preparations that contain more rapidly dividing
cells (n = 27 except for CD119 (n = 21)) (Figure 3K-M).
Moreover, the PDT correlated negatively with the per-
centage of CD146+ cells within the BM-MSC prepara-
tions (n = 27) (Figure 3N).
High-clonogenic BM-MSCs are smaller, divide more
rapidly and are more frequent in BM-MSC preparations
from younger, female donors
To assess the clonogenic activity of the BM-MSC prepa-
rations, a total of 50 BM donors were analyzed (donor
distribution shown in Additional file 3: Table S1). Com-
paring all ages and both genders, MSC preparations
from the BM of younger donors trended toward more
colony forming cells than MSC preparations from older
donors (n = 50) (Figure 4A). Comparing age groups in-
cluding both genders, significantly more colonies could
be detected in young (<45 years) donors (12.3% ± 7.1%
SD; n = 11) compared to middle-aged (45 to 65 years;
5.6% ± 4.5% SD; n = 26) and older donors (>65 years;
6.9% ± 4.0% SD; n = 13) (Figure 4B). In BM-MSC prepa-
rations from female donors more colony forming cells
could be detected (9.3% ± 6.2% SD; n = 23) compared to
BM-MSC preparations from male donors (5.9% ± 4.8% SD)
(n = 27) (Figure 4C). Age group specific analyses for each
gender confirmed that more colonies could be detected in
young female donors (<45 years) compared to older donors
(Figure 4D,E). The clonogenic potential of the cells
within the BM-MSC preparations was inversely related
to the population doubling time (n = 42) and the cell
diameter (n = 22) indicating a more rapid growth of
smaller, high-clonogenic BM-MSC subpopulation(s)
(Figure 4F,G).
The percentage of CD10+, CD71+, CD106+, CD119+
CD146+, CD166+ and CD271+ cells correlated positively
with the clonogenic potential of the BM-MSCs (n = 31
except for CD119 (n = 25)) (Figure 4H-N). The specific
antibody mediated fluorescence per cell (ΔGeo Mean) of
CD29, CD44, CD119, CD146, CD166 and HLA ABC
correlated positively with the clonogenic potential of the
MSCs (n = 31 except for CD119 (n = 25)) (Figure 4O-T).
These data suggest that CD10, CD29, CD44, CD71,
CD106, CD119, CD146, CD166, CD271 and HLA ABC
indicate BM-MSC preparations with high clonogenic
potential.
The pooled human serum (PHS) used in our study
was obtained from male donors only, consequently
containing more testosterone (16.18 nmol/l) than would
be expected in PHS from female individuals (normal
range of testosterone in male serum: 9 to 30 nmol/l;
normal range of testosterone in female serum: 0.5 to
2.6 nmol/l). Moreover, the PHS contained 75.12 pg/mlbasic fibroblast growth factor (bFGF). To investigate
possible contributions of testosterone and/or bFGF to
the observed differences between female and male BM-
MSCs, we compared androgen receptor and fibroblast
growth factor receptor 3 (FGFR3) expression of BM-
MSC preparations by ELISA. No difference was
detected in the androgen receptor or FGFR3 expression
nor was there any significant correlation of these receptors
to donor age (n = 14 (7 female, 7 male)) (see Additional
file 4: Figure S1).
BM-MSC preparations from female donors demonstrated
higher levels of allogeneic T cell proliferation suppression
BM-MSCs from both female and male donors signifi-
cantly suppressed the proliferation of activated allogen-
eic T cells obtained from six different donors. BM-MSCs
from female donors (nine donors, tested with allogeneic
T cells from two different donors; n = 18) showed a sig-
nificantly increased suppression of T cell proliferation
compared to BM-MSCs from male donors (eight donors,
tested with allogeneic T cells from two different donors;
n = 16) (Figure 5A). No correlation of the donor age to
the potential to suppress T cell proliferation could be
detected (Figure 5B). Upon co-culturing of BM-MSCs
from older donors with activated allogeneic T cells more
interleukin IL-6 could be detected in the supernatant
compared to BM-MSCs from younger donors that were
co-cultured with activated T cells (n = 17) (Figure 5C).
No differences could be detected with respect to IL-2,
IL-4, IL-8, IL-10, IFN-γ and TNF-α concentrations in
the supernatants of BM-MSCs cultured with or without
activated allogeneic T cells (data not shown).
BM-MSCs from both female and male donors
expressed IDO 1 mRNA but no IDO 2 mRNA (data not
shown). Although a trend toward a negative correlation
was observed, no significant correlation of IDO 1 mRNA
expression to T cell proliferation could be detected (n = 8)
(Figure 5D). No difference of IDO 1 mRNA expression
from male BM-MSC donors compared to female BM-
MSC donors could be detected and no correlation of the
IDO 1 mRNA expression to the donor age could be ob-
served (n = 22) (Figure 5E,F).
The in vitro mesodermal differentiation capacity of BM-
MSCs is not affected by donor age and donor gender but
by phenotype
No donor age or gender related differences could be
detected for the adipogenic, osteogenic and chondrogenic
in vitro differentiation capacity of the BM-MSC prepara-
tions as analyzed by lineage specific staining (Oil Red O for
adipogenesis; Alizarin Red for osteogenesis, and Safranain
O for chondrogenesis (n = 32); Figure 6A-E) and no statis-
tically significant differences could be detected for the
lineage specific mRNA induction (LPL (n = 44) and PPARγ
Figure 4 (See legend on next page.)
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Figure 4 Analyses of clonogenic potential. Comparing all ages and both genders, MSC preparations from the BM of younger donors trended
toward more colony forming cells than MSC preparations from older donors (n = 50) (A). Spearman two-tailed correlation test. Comparing age
groups including both genders, significantly more colonies could be detected in young donors (<45 years) (n = 11) compared to middle-aged
(n = 26) and older donors (n = 13) (B). ANOVA analysis of variance followed by Tukey’s Multiple Comparison Test (*P <0.05; **P <0.01). Error bars:
SD. In BM-MSC preparations from female donors more colony forming cells could be detected (n = 23) compared to BM-MSC preparations from
male donors (n = 27) (C). Two-tailed Student’s t-test (*P <0.05). Error bars: SD. Age-group specific analyses for each gender confirmed that more
colonies could be detected in young female donors (<45 years) compared to older donors (D, E). ANOVA analysis of variance followed by Tukey’s
Multiple Comparison Test (*P <0.05). Error bars: SD. The clonogenic potential of the cells within the BM-MSC preparations was negatively correlated to
the population doubling time (n = 42) and the cell diameter (n = 22) (F, G). Spearman two-tailed correlation test (**P <0.01; ****P <0.0001). The
percentage of CD10+, CD71+, CD106+, CD119+ CD146+, CD166+ and CD271+ cells correlated positively with the clonogenic potential of the BM-MSCs
(n = 31 except for CD119 (n = 25)) (H-N). The specific antibody mediated fluorescence per cell (ΔGeo Mean) of CD29, CD44, CD119, CD146, CD166
and HLA ABC correlated positively with the clonogenic potential of the MSCs (n = 31 except for CD119 (n = 25)) (O-T). Spearman two-tailed
correlation test (*P <0.05; **P <0.01; ***P <0.001; ****P <0.0001).
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for osteogenesis; SOX9 (n = 47) and COLL2 (n = 32) for
chondrogenesis; Figure 6F-Q).
The percentage of CD10+ cells (n = 27) and the specific
antibody mediated fluorescence per cell (ΔGeo Mean) of
CD119 (n = 22) correlated positively with the induction ofFigure 5 Analyses of the immunosuppressive potential of MSCs. MSC
proliferation of activated allogeneic T cells. MSCs from female donors (n =
proliferation than MSCs from male donors (n = 16). Data are normalized to
variance followed by Tukey’s Multiple Comparison Test (*P <0.05; ***P <0.0
suppress T cell proliferation could be detected (B). Upon co-culturing of MSC
detected in the supernatant compared to MSCs from younger donors that w
correlation test (*P <0.05). Although a trend toward a negative correlation wa
proliferation could be detected (n = 8) (D). Spearman two-tailed correlation te
compared to female MSC donors could be detected (n = 22) (E). Two-tailed S
expression to the donor age could be observed (n = 22) (F). Spearman two-taPPARγ mRNA under adipogenic differentiation (Additional
file 5: Figure S2A-D). Moreover, the percentage of GD2+
cells and the specific antibody mediated fluorescence
per cell (ΔGeo Mean) of GD2 correlated negatively with
the induction of LPL mRNA under adipogenic differen-
tiation (n = 26) (Additional file 5: Figure S2E,F).s from both female and male donors significantly suppressed the
18) showed a significantly higher potency to suppress T cell
the proliferation index of PBMNCs alone (A). ANOVA analysis of
01). Error bars: SD. No correlation of the donor age to the potential to
s from older donors with activated allogeneic T cells more IL-6 could be
ere co-cultured with activated T cells (n = 17) (C). Spearman two-tailed
s observed, no significant correlation of IDO 1 mRNA expression to T cell
st. No difference of IDO 1 mRNA expression from male MSC donors
tudent’s t-test. Error bars: SD. No correlation of the IDO 1 mRNA
iled correlation test.
Figure 6 Mesodermal differentiation potential of MSCs. No donor age or gender related differences could be detected for the adipogenic,
osteogenic and chondrogenic in vitro differentiation capacity of the MSC preparations as analysed by lineage specific staining (Oil Red O for
adipogensis; Alizarin Red for osteogenesis, and Safranain O for chondrogenesis (n = 40); differentiation: A, C, E; negative controls: B, D) and no
statistically significant differences could be detected for the lineage specific mRNA expression (LPL (n = 44) and PPARγ (n = 48) for adipogenesis;
OPN (n = 17) and AP (n = 41) for osteogenesis; SOX9 (n = 47) and COLL2 (n = 32) for chondrogenesis; F-Q). Two-tailed Student’s t-test and
Spearman two-tailed correlation test. Error bars: SD. Scale bars: 100 μm.
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affects the secretion of trophic factors
BM-MSCs secreted the highest concentrations of VEGF-
A and HGF, followed by LIF, Angiopoietin-1, bFGF and
NGFB. BMP4 could not be detected in the supernatants
of the tested BM-MSC preparations (six female, five
male; age: 50.9 y ± 12.7 y SD) (see Additional file 6:
Figure S3A). Correlation analyses of the six secreted fac-
tors to markers potentially defining BM-MSC subpopula-
tions (Figure 1) revealed a significant negative correlation
of HGF secretion to the expression of CD71, CD140b and
Galectin 1 (n = 11 except for Galectin 1 (n = 9)) (see
Additional file 6: Figure S3B), and no positive correl-
ation of the tested markers to the secretion of trophic
factors could be identified. Moreover, neither donor age
nor gender affected the secretion of trophic factors (see
Additional file 6: Figure S3C,D). Interestingly, we
detected Angiopoietin-1 in the supernatants of only 4
of the 11 tested BM-MSC populations (see Additional
file 7: Table S2). Age and gender distribution within the
“secretor” group (53.3 y ± 16.6 y; two female, two male)
and the “non-secretor” group (49.6 y ± 9.6 y; three female,
four male) was balanced, and no correlation of the marker
expression to the Angiopoietin-1 “(non-)secretor” statusof the BM-MSCs could be identified (see Additional file 6:
Figure S3E,F).Oct4, Nanog and Prdm14 mRNA expression is low
compared to pluripotent stem cells and is not affected by
age or gender in BM-MSC preparations in vitro
Oct4, Nanog and Prdm14 mRNA was expressed by BM-
MSCs in vitro whereas SOX2 mRNA could only be
detected at minimal level in 5 out of 18 analyzed BM-
MSC preparations. The BM-MSCs expressed signifi-
cantly more Oct4 mRNA than Nanog mRNA or Prdm14
mRNA however, no significant difference in Nanog
mRNA expression compared to Prdm14 mRNA ex-
pression could be detected (n = 28 except for Prdm14
(n = 23)) (Figure 7A). Compared to pluripotent human
ESCs (HUES9) and a human pluripotent germ cell
tumor line (NCCIT) the expression of Oct4 mRNA,
Nanog mRNA and Prdm14 mRNA was much lower in
BM-MSCs. HUES9 cells and NCCIT cells expressed 103
to 104 times more Oct4, Nanog and PRDM14 mRNA than
BM-MSCs (Figure 7B-D). Moreover, no correlation of the
expression of Oct4, Nanog and Prdm14 mRNA to donor
age (n = 28 except for Prdm14 (n = 23)) (Figure 7E-G) or
Figure 7 (See legend on next page.)
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Figure 7 Expression of Oct4, Nanog and Prdm14 mRNA and functional relevance. The MSCs expressed significantly more Oct4 mRNA than
Nanog or Prdm14 mRNA; however, no significant difference in Nanog mRNA expression compared to Prdm14 mRNA expression could be
detected (n = 28 except for Prdm14 (n = 23)) (A). Compared to pluripotent HUES9 cells and pluripotent NCCIT cells the expression of Oct4 mRNA,
Nanog mRNA and Prdm14 mRNA was much lower in MSCs (B-D). Compared to NCCIT cells the HUES9 cells expressed more Oct4 mRNA, Nanog
mRNA and Prdm14 mRNA (B-D). ANOVA analysis of variance followed by Tukey’s Multiple Comparison Test (*P <0.05; ***P <0.001). Error bars: SD.
No correlation of the expression of Oct4, Nanog and Prdm14 mRNA to donor age (n = 28 except for Prdm14 (n = 23)) (E-G) or any gender-related
differences could be detected (n = 28 except for Prdm14 (n = 23)) (H-J). The clonogenic potential of MSCs correlated positively to the expression
of Prdm14 mRNA (n = 18) but not to Oct4 (n = 24) or Nanog mRNA (n = 24) (K-M). Two-tailed Student’s t-test and Spearman two-tailed
correlation test (**P <0.01). Error bars: SD.
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except for Prdm14 (n = 23)) (Figure 7H-J).
Prdm14 mRNA expression is positively correlated to the
clonogenic potential of MSCs in vitro
The clonogenic potential of BM-MSCs correlated posi-
tively to the expression of Prdm14 mRNA (n = 18) but not
to Oct4 (n = 24) or Nanog mRNA (n = 24) (Figure 7K-M).
Interestingly, the clonogenic potential of the BM-MSC
preparations did not correlate to the induction of lineage
specific mRNA expression (LPL, PPARγ, OPN, AP, SOX9
and COLL2) under differentiation in vitro (data not
shown; summary in Table 1). Moreover, the expression of
Oct4, Nanog and Prdm14 mRNA in undifferentiated BM-
MSCs did not correlate to the induction of lineage specific
mRNA expression under differentiation of the respective
MSC preparations in vitro (LPL, PPARγ, OPN, AP, SOX9
and COLL2) except for a negative correlation of SOX9
mRNA expression under chondrogenic differentiation to
Oct4 (n = 25) and Prdm14 mRNA (n = 19) expression
(data not shown; summary in Table 1).Table 1 Not significantly correlated parameters
Parameter 1 Parameter 2
Donor age Diameter
Donor age PDT
Donor age Secretion of IL-2, IL-4, IL-8, IL-10
Donor age Expression of Oct4 mRNA
Donor age Expression of Nanog mRNA
Donor age Expression of Prdm14 mRNA
Donor gender Antigen density per cell(ΔGeo
Donor gender Secretion of IL-2, IL-4, IL-6, IL-8,
Donor gender Secretion of IL-2, IL-4, IL-6, IL-8,
allogeneic T cells)
CFU-F Induction of LPL, PPARγ, OPN, A
CFU-F Expression of Oct4 mRNA
CFU-F Expression of Nanog mRNA
Expression Oct4 mRNA (undifferentiated) Induction of LPL, PPARγ, OPN, A
Expression Nanog mRNA (undifferentiated) Induction of LPL, PPARγ, OPN, A
Expression Prdm14 mRNA (undifferentiated) Induction of LPL, PPARγ, OPN, A
Donor age, donor gender Secretion of Angiopoietin-1, NGHuman BM-MSCs show no telomerase activity in vitro
No telomerase activity could be detected in 24 analyzed
BM-MSC preparations (11 female, 13 male; average age
53.7 years ± 12.7 years SD) (data not shown).
Discussion
BM-MSC preparations in vitro are known to be a
heterogenic mix of adherently growing cells sharing
similar, that is, spindle shaped, morphology [25]. Studies
have revealed that BM-MSC preparations in vitro are
composed of poorly defined subpopulations, and that a
minority of clonally expanded MSCs showed full “tri-
lineage” (adipogenic, osteogenic and chondrogenic) dif-
ferentiation potential [12,14,26,27], pointing toward
functional differences of BM-MSC subpopulations. In
addition to intra-individual heterogeneity, donor-related
variations of differentiation potential and growth kinetics
of MSC preparations point toward significant inter-
individual heterogeneity [11,12]. Studies that identify in vivo
stromal cell subpopulations are rare and focus on very few
markers [24,28,29]. Attempts were, therefore, made to findn
25
52





IL-10, TNFα, IFNγ(BM-MSCs with stimulated allogeneic T cells) 17
IL-10, TNFα, IFNγ(BM-MSCs alone or with stimulated 17
P, SOX9 and COLL2 mRNA (differentiation) 13 to 39
24
24
P and COLL2 mRNA (differentiation) 25
P, SOX9, and COLL2 mRNA (differentiation) 25
P and COLL2 mRNA (differentiation) 19
FB, LIF, bFGF, VEGF-A, HGF 11
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ulations for possible clinical use [13,15,23,30-32], resulting
in greatly improved characterization of MSC prepara-
tions in vitro. Whether a distinct phenotype correlated
with specific functional properties was addressed by
sorting and analyzing few subpopulations but likely left
many uncharacterized. As to heterogeneity, in vitro
data are not conclusive due to study-to-study variations
on BM-MSC performance (for example, differentiation
potential) and reproducibility challenges. Therefore, it
is difficult to understand the in vivo nature and com-
position of the BM stroma as well as the impact of
in vitro selection and culture conditions on BM-MSC
subpopulations. Analysis of sorted BM-MSC subpopu-
lations, requiring thorough optimization of culture con-
ditions for each subpopulation, is one option. We
analyzed great numbers of human BM-MSC preparations
to identify statistically robust correlations of phenotype,
donor gender and age to functional properties.
We identified three surface marker patterns on adher-
ent BM-MSCs in vitro: (1) markers uniquely expressed
by all cells; (2) markers not expressed by any cells; and
(3) markers heterogeneously expressed by subpopulations.
Here we saw prominent inter-individual heterogeneity.
With respect to distinct phenotypes of BM-MSC subpop-
ulations, these markers appear most interesting and prob-
ably allow correlation of MSC preparations to potency.
The great heterogeneity of MSC preparations still ham-
pers the development of marker-based potency assays
for MSCs, such as the well-established quantification of
CD34+ cells in hematopoietic stem cell preparations.
Quantification of cells expressing (or lacking) these
markers allowed us to distinguish markers expressed on
rare (≤10%) subpopulations versus those on more fre-
quent subpopulations.
To what extent, if any, adult BM-MSCs exhibit stem
cell properties (that is, self-renewal and broad differenti-
ation capacity) has been under debate for over a decade
[33]. Despite difficulties in distinguishing self-renewal
from proliferation or selection of immortalized clones,
studies suggest MSCs might have self-renewal capacity
[34]. Clonal growth is associated with self-renewal, regu-
lated by factors such as LIF and BMPs [35,36]. However,
determination of a stem cell character cannot be based
on clonal growth alone because the differentiation po-
tential of cell clones derived from BM is highly variable
and only a minority of clones exhibit mesodermal “tri-
lineage” differentiation capacity [26]. Regarding differen-
tiation capacity, functional data on non-mesodermal or
myogenic differentiation of human BM-MSCs are miss-
ing or controversial [10,19,37] and no study has reported
on differentiation of adult human BM-MSCs, isolated by
plastic adherence, into cells or tissue(s) of all three germ
layers upon blastocyst transfer or teratoma formationin vivo. The surface antigen SSEA-4 and the transcrip-
tion factors Oct4, Nanog and Prdm14 are regarded as
stem cell markers [33,38,39]. SSEA-4+ MSCs [40,41],
multipotent adult progenitor cells (MAPC), marrow-
isolated adult multi-lineage inducible cells (MIAMI) and
very small embryonic-like (VSEL) stem cells were shown
to express stem cell markers, and could be differentiated
into various mesodermal and non-mesodermal cell types
[42-47]. We have also shown in vivo that adult human
BM harbors distinct stromal cell entities expressing
Oct4, Nanog and SSEA-4 on the protein/antigen level
[48]. To put these observations into context with BM-
MSCs in vitro, we analyzed clonogenic potential, meso-
dermal differentiation potential, expression of stem cell
markers, and telomerase activity of the BM-MSC prepa-
rations. A variety of antigens, but not SSEA-4, were cor-
related to BM-MSC preparations with high clonogenic
potential. Notably, the clonogenic potential of BM-
MSCs did not correlate to differentiation potential or
telomerase activity, and BM-MSCs expressed much
lower levels of stem cell marker mRNA compared to
pluripotent stem cells. Our data suggest that BM-MSC
preparations isolated and cultured under standard
conditions do not contain cells with stem cell proper-
ties, in possible contrast to MAPC, MIAMI or VSEL
stem cells that require specialized isolation and cul-
ture conditions.
Our correlation analyses suggest the presence of BM-
MSC phenotypes with either higher (CD10, CD119) or
lower (GD2) adipogenic differentiation potential in vitro.
Human BM harbors adipogenic stromal cells expressing
CD10 but not GD2 in vivo [48]. We speculate that this
cell type was, among others, positively selected by plastic
adherence thereby being able to give rise to terminally dif-
ferentiated adipocytes when exposed to the respective dif-
ferentiation medium in vitro. To verify this hypothesis, we
suggest future studies on sorted cells investigating the
adipogenic differentiation potential of CD10+CD119+GD2-
and CD10-CD119-GD2+ BM-MSC subpopulations.
BM-MSC-mediated immunomodulation mainly comes
as potent immunosuppression [18,49]. Therefore, BM-
MSCs are used in the clinic for treatment of graft-ver-
sus-host disease (GvHD) [6,50] and multiple sclerosis
(MS) [9,51,52], and clinical trials to treat type-1 diabetes
(T1D) are underway. Here we investigated the expres-
sion of factors in BM-MSC preparations that are in-
volved in BM-MSC immunomodulation. We show for
the first time that human BM-MSCs express IDO1 but
not IDO2, consistent with the fact that IDO1 but not
IDO2 is involved in tryptophan degradation [53].
François et al. [54] reported on the great variability of
seven BM-MSC preparations to suppress T cell prolifera-
tion. Moreover, in analyzing 21 data points, they ob-
served a positive correlation between IDO production by
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ation [54]. In our study, despite donor-to-donor variabil-
ity, MSCs from female donors showed significantly
increased suppression of T cell proliferation compared
to male donors. Although we observed only trends in
greater IDO1 mRNA expression in female BM-MSCs
and stronger suppression of T cell proliferation by BM-
MSCs expressing more IDO1 mRNA, we hypothesize
that the superior immunosuppressive properties of fe-
male BM-MSCs might be mediated by IDO1.
Galectin 1, located either on the surface or in the
cytoplasma of BM-MSCs, plays an important role in
MSC-mediated suppression of T cell proliferation [55]
and Galectin 1+ stromal cells contribute to the
hematopoietic niche in the BM [56]. We detected
Galectin 1, and for the first time on human BM-MSCs,
PDL-1 and PDL-2 on approximately 50% of the cells
within BM-MSC preparations, however, at relatively low
densities per cell. Activation of Programmed Death 1
(PD-1) by the negative co-stimulatory molecules PDL-1
and PDL-2 leads to inactivation of T cells [57] and mur-
ine BM-MSCs were shown to exert their immunosup-
pressive function using the PD-1 pathway [58,59]. We
did not observe significant correlations of function, in
particular immunomodulation, to the expression of
Galectin 1, PDL-1 or PDL-2 on BM-MSCs. However,
our results do not negate potential contributions of
these molecules in human BM-MSC function as the
functional analyses of the immunomodulatory properties
were performed with fewer BM-MSC preparations, pos-
sibly hampering the identification of significant differ-
ences or correlations.
Many functional parameters of BM-MSCs did not cor-
relate to donor age or gender (Table 1). We, however,
found that high-clonogenic BM-MSCs were smaller, di-
vided more rapidly and were more frequent in BM-MSC
preparations from younger, female donors. These find-
ings correspond to a study that reported a higher growth
rate and clonogenic potential of BM-MSCs from chil-
dren versus adults [60]. Alves et al. [61] recently associ-
ated several in vitro characteristics of BM-MSCs to
donor age. We found no correlation of donor age to
adipogenic, osteogenic and chondrogenic differentiation
in vitro as confirmed by an extended panel of lineage
specific markers. We identified several differentially
expressed proteins on BM-MSCs from younger donors
compared to older donors. Interestingly, none of these
targets correlated to donor age at the mRNA level in the
Alves et al. study [61]. Besides possible age-related post-
transcriptional impact on protein expression, the expos-
ure of fetal bovine serum plus addition of bFGF in this
study (versus PHS without any additional growth factors
in our study) could have contributed to these discrepant
results.Studies have shown that MSC function in vivo is medi-
ated by secreted trophic factors [7,62-66] although few
studies, mainly on rodent MSCs, report gender di-
morphism of MSC secretion of trophic factors or cyto-
kines [67,68]. We propose the pre-transplantation
assessment of BM-MSC-secreted trophic factors as a
clinically relevant issue. We, therefore, analyzed the se-
cretion of factors shown to mediate tissue regeneration
and immunomodulation: VEGF-A (angiogenesis), HGF
(angiogenesis, anti-proliferative effects on T-cells), LIF
(induction of Foxp3+ T cells, anti-proliferative effects on
T-cells), Angiopoietin-1 (angiogenesis), bFGF (angiogen-
esis, cell proliferation and migration), BMP4 (cell prolif-
eration, osteogenesis) and NGFB (neuroprotection)
[18,22]. We detected Angiopoietin-1 in the supernatants
of only 4 of 11 tested BM-MSC preparations thereby
identifying “Angiopoietin-1-secretor” and “Angiopoietin-
1-non-secretor” BM-MSC preparations. Angiopoietin-1
secretor status was not determined by age, gender or
marker expression. For further characterization we rec-
ommend RNA microarray screening analyses followed
by functional assessments in vitro and in vivo. Previous
studies reported on rat BM-MSC secretion of BMP4, a
factor in proliferation and differentiation [69,70]. Inter-
estingly, we could not detect BMP4 in the supernatants
of human BM-MSC preparations, which suggests that
secreted BMP4 might not be an ideal target to assess hu-
man BM-MSC preparations in vitro.
PDGF and bFGF play pivotal roles in MSC prolifera-
tion [71,72]. We detected CD140b (PDGFRb) on nearly
all cells in the BM-MSC preparations. For CD140a
(PDGFRa) expression, though possibly defining a sub-
population, we did not find a difference in gender distri-
bution or correlation to BM-MSC proliferation. We,
therefore, lack evidence of a crucial role for PDGF in
gender dimorphism of BM-MSC proliferation. We then
evaluated the possible influence of bFGF on BM-MSC
proliferation. FGF receptors play important roles in pro-
liferation, differentiation and possibly self-renewal of
MSCs [73-75]. Kim et al. [73] showed that human
synovium-derived MSCs transcribed FGFR 1–4 mRNA
but expressed only FGFR3 at the protein level. We ana-
lyzed FGFR3 protein expression in BM-MSCs without
detecting differences between female and male donors,
or identifying a correlation to donor age. The PHS used
in our study was obtained from male donors only, with
consequently more testosterone than expected from fe-
male individuals. To evaluate the role of testosterone in
BM-MSC gender dimorphism, we analyzed the expression
of androgen receptors in BM-MSCs. We found no differ-
ence between genders or a correlation to donor age. This
corresponds to studies reporting that treatment with sex
hormones (dihydrotestosterone, 17β-estradiol) did not in-
crease the proliferative capacity of human MSCs [76,77].
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functional properties of BM-MSCs, that is, CD119,
CD146 and HLA ABC (Table 2). We suggest future
studies on sorted CD119+, CD146+ and HLA ABC+ BM-
MSCs to analyze the expression profile of genes that me-
diate therapeutic potential as well as performance in
functional assays.Conclusions
It has become evident that the currently most widely
used BM-MSC isolation technology, that is, culture of
plastic adherent BM-cells and removal of non-adherent
BM-cells, is a significant selection process for BM-MSC
subpopulations. Hereby, rare MSC subpopulations that
possibly feature stem cell-related properties will be lost.
On the other hand, a heterogenic mix of MSC subpopu-
lations adapts very well to these conditions and prolifer-
ates in vitro as BM-MSC preparations. By analyzing and
extensively characterizing a great number of BM-MSC
preparations, we overcame a major challenge in research
on primary BM-MSCs of donor-to-donor variation. We
hereby identify phenotypes featuring functional proper-
ties that are partially donor-related, and propose future
studies on CD119+, CD146+, HLA ABC+ BM-MSC sub-
populations, as well as on Angiopoietin-1 secreting and
non-secreting BM-MSC preparations.
For clinical production of BM-MSCs, markers that
correlate positively and negatively to functional proper-
ties of BM-MSC preparations and markers that define
rare subpopulations could be useful for the development
of assays to define release or characterization criteria for
quality control purposes and clinical applications. More-
over, the gender-related effect on growth kinetics of BM-
MSCs could help to plan their scale-up production.Table 2 Assignment of functional and phenotypical
properties to CD119, CD146 and HLA ABC expression
Marker Parameter Correlation n
CD119 (IFNγR1) antigen density per










CD146 (MCAM) antigen density per
cell (ΔGeo Mean Fluorescence)
CFU-F Positive 31
PDT* Negative 27
Donor age Negative 34





*Percentage of antigen positive cells.For clinical applications, our data might, on one hand,
provide evidence to initiate clinical phase I trials com-
paring the immunomodulatory potential of allogeneic
BM-MSC preparations from female to male donors for
diseases such as GvHD, MS or T1D. On the other hand,
donor age or gender might not affect BM-MSC perform-
ance in clinical applications where BM-MSC-derived
trophic factors are considered to contribute substantially
to efficacy of the cell therapy (for example, stroke or
myocardial infarction).Additional files
Additional file 1: Figure S4. Flow cytometry gating strategy. FSC–SSC
gating to separate debris from intact cells (G1). Dead cells were excluded
by uptake of 7-AAD (G2 on 7-AAD negative (= live) cells). Percentage
analysis of antigen-positive cells and fluorescence intensity was
performed with FlowJo-7.2.5 software. For compensation of unspecific
antibody binding, the positivity of the respective matched isotype
control was subtracted from all samples.
Additional file 2: Figure S5. Flow cytometry density plots. Density
plots from flow cytometric analysis show a representative BM-MSC
preparation (P1). Overlay density plots show gated cells after excluding
non-viable cells and debris. Green: specific antibody; red: isotype control.
Additional file 3: Table S1. Donor distribution and data for CFU-F
analyses.
Additional file 4: Figure S1. Expression of androgen receptor and
FGFR3 by BM-MSCs. No difference was detected in androgen receptor
and FGFR3 expression between BM-MSC preparations of female and
male donors (A, B) and no significant correlation was found between
these receptors and donor age (C, D) (n = 14 (7 female, 7 male)). Lower
detection limits (ELISA): Androgen receptor: 113 pg/ml; FGFR3: 55 pg/ml.
Two-tailed Student’s t-test and Spearman two-tailed correlation test, error
bars: SD.
Additional file 5: Figure S2. Adipogenic differentiation potential of
MSCs. The percentage of CD10+ cells (n = 27) and the specific antibody
mediated fluorescence per cell (ΔGeo Mean) of CD119 (n = 22)
correlated positively with the induction of PPARγ mRNA under
adipogenic differentiation (A-D). Moreover, the percentage of GD2+ cells
and the specific antibody mediated fluorescence per cell (ΔGeo Mean) of
GD2 correlated negatively with the induction of LPL mRNA under
adipogenic differentiation (n = 26) (E, F). Hereby, we identified two
phenotypes with either higher (CD10, CD119) or lower (GD2) adipogenic
differentiation potential within the BM-MSC preparations. Spearman two-
tailed correlation test (*P <0.05; **P <0.01).
Additional file 6: Figure S3. Secretion profile of MSC trophic factors.
BM-MSCs secreted the highest concentrations of VEGF-A and HGF,
followed by LIF, Angiopoietin-1, bFGF and NGFB (n = 11) (A). Correlation
analyses of the secreted factors to markers potentially defining MSC
subpopulations revealed a significant negative correlation for HGF
secretion to the expression of CD71, CD140b and Galectin 1 (n = 11
except for Galectin 1 (n = 9)) (B); no positive correlation of the tested
markers to the secretion of trophic factors was identified. Neither donor
age nor gender affected the secretion of trophic factors (C, D); no
correlation of the marker expression to the Angiopoietin-1 “(non-)
secretor” status of the MSCs was identified (n = 11) (E, F). Lower
detection limits (Luminex® and ELISA): NGF-b: 3.9 pg/ml; LIF: 2.5 pg/ml;
FGF-b: 13.2 pg/ml; VEGF-A: 11.2 pg/ml; HGF: 2.2 pg/ml; Angiopoietin-1:
3.45 pg/ml; BMP4: 1.04 pg/ml. ANOVA analysis of variance followed by
Tukey`s Multiple Comparison Test, Two-tailed Student’s t-test and
Spearman two-tailed correlation test (*P <0.05; **P <0.01; ***P <0.001).
Error bars: SD.
Additional file 7: Table S2. Donor variations and data of Angiopoietin-
1 secretion.
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(b)FGF(R): (basic) fibroblast growth factor (receptor); BM: Bone marrow;
BMP4: Bone morphogenetic protein 4; BrdU: Bromodeoxyuridine; CD: Cluster
of differentiation; cDNA: Complimentary deoxyribonucleic acid; CFU-
F: Colony-forming unit fibroblast; COLL2: Collagen 2;
EDTA: Ethylenediaminetetraacetic acid; ELISA: Enzyme-linked immuno
sorbent assay; ESCs: Embryonic stem cells; GvHD: Graft-versus-host disease;
HGF: Hepatocyte growth factor; HLA: Human leucocyte antigen;
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; IDO: Indoleamine 2,3-
dioxygenase; IFNγ-R1: Interferon γ-receptor 1; IL-: Interleukin-; LIF: Leukemia
inhibitory growth factor; LPL: Lipoprotein lipase; MEM: Minimal essential
medium; MSCA: Mesenchymal stem cell antigen; MSCs: Mesenchymal
Stromal Cells; mRNA: Messenger ribonucleic acid; MS: Multiple sclerosis;
NGFB: Nerve growth factor; Oct4: Octamer-binding transcription factor 4;
OPN: Osteopontin; P: Passage; PBS: Phosphate buffered saline;
PCR: Polymerase chain reaction; PDGFR: Platelet-derived growth factor
receptor; PDT: Population doubling time; PD(L)-1: Programmed death
(ligand)1; PE: Phycoerythrin; PHS: Pooled human serum; PPAR-γ: Peroxisome
proliferator-activated receptor-γ; Prdm14: PR domain containing 14;
SCM: Standard culture medium; SD: Standard deviation; Sox2/9: SRY (sex
determining region Y)-box 2/9; SSEA-4: Stage-specific embryonic antigen 4;
T1D: Type-1 diabetes; VEGF-A: Vascular endothelial growth factor-A.
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